Cargando…

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer

BACKGROUND: Bicalutamide is a nonsteroidal antiandrogen widely used as a first-line clinical treatment for advanced prostate cancer (PCa). Although patients initially show effective responses to bicalutamide treatment, resistance to bicalutamide frequently occurs and leads to the development of cast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Lei, Peng, Yanfei, Yang, Kuo, Cao, Jiasong, Du, Xiaoling, Liang, Zhixian, Shi, Jiandang, Zhang, Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661764/ https://www.ncbi.nlm.nih.gov/pubmed/36376959 http://dx.doi.org/10.1186/s12964-022-00979-0

Ejemplares similares

Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer
por: Shen, Yongmei, et al.
Publicado: (2019)

CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation
por: Lin, Qimei, et al.
Publicado: (2022)

The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer
por: Lin, Qimei, et al.
Publicado: (2022)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer
por: Johnson, Tamara Jane, et al.
Publicado: (2013)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
por: Li, Yuezheng, et al.
Publicado: (2023)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression
por: Chamard-Jovenin, Clémence, et al.
Publicado: (2015)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure
por: Muramatsu, Tomoaki, et al.
Publicado: (2019)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Bicalutamide-induced hepatotoxicity: A rare adverse effect
por: Hussain, Salwa, et al.
Publicado: (2014)

Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia
por: Gomez-Zubiaur, Alba, et al.
Publicado: (2023)

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
por: Dijkstra, Siebren, et al.
Publicado: (2016)

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?
por: Lewis, R., et al.
Publicado: (2012)

Data-Driven Modeling of the Bicalutamide Dissolution from Powder Systems
por: Mendyk, Aleksander, et al.
Publicado: (2020)

Physicochemical Profile of Antiandrogen Drug Bicalutamide: Solubility, Distribution, Permeability
por: Volkova, Tatyana V., et al.
Publicado: (2022)

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
por: Kang, Yu Jin, et al.
Publicado: (2014)

Bicalutamide Elicits Renal Damage by Causing Mitochondrial Dysfunction via ROS Damage and Upregulation of HIF-1α
por: Chen, Kuan-Chou, et al.
Publicado: (2020)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
por: Beebe-Dimmer, Jennifer L., et al.
Publicado: (2018)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
por: Rocha, Sandra M., et al.
Publicado: (2023)

Molecular Disorder of Bicalutamide—Amorphous Solid Dispersions Obtained by Solvent Methods
por: Szafraniec, Joanna, et al.
Publicado: (2018)

Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
por: Jamalpoor, Amer, et al.
Publicado: (2021)

Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins
por: De Gaetano, Federica, et al.
Publicado: (2022)

Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice
por: Galbiati, Mariarita, et al.
Publicado: (2023)

Optimization, characterization, and follicular targeting assessment of tretinoin and bicalutamide loaded niosomes
por: Ghasemiyeh, Parisa, et al.
Publicado: (2023)

The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients
por: Czogalla, Bastian, et al.
Publicado: (2018)

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
por: Culig, Z, et al.
Publicado: (1999)

Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
por: Beebe-Dimmer, Jennifer L., et al.
Publicado: (2018)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan
por: Ünal, Kemal, et al.
Publicado: (2020)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Multi-Matrix Approach for the Analysis of Bicalutamide Residues in Oncology Centers by HPLC–FLD
por: Portilha-Cunha, M. Francisca, et al.
Publicado: (2021)

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
por: Brait, Mariana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a5so3t65pim7dtb27gd38t7g1s